Anita Katharina Wagner, PharmD, MPH, DrPH

Anita Katharina Wagner is Associate Professor in the Division of Health Policy and Insurance Research at the Department of Population Medicine at Harvard Medical School and the Harvard Pilgrim Health Care Institute. She directs the organizational Ethics Program of Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, two non-profit health insurers in the Eastern United States, and is a member of the Harvard Ethics Leaders Group.  Dr. Wagner co-directs the Department of Population Medicine Center for Cancer Policy and Program Evaluation (CarPE), is a co-founding member of the Pharmaceutical Policy Lab the LSE, and a Docent at Tampere University.

With colleagues across the world, Dr. Wagner conducts empirical research to generate evidence for answering challenging health system questions.  Their work, frequently in large databases, evaluates impacts of insurance and other policy changes on medicines’ availability, access, affordability, and use, in the United States, Europe, China, and elsewhere.  The team also seeks to improve communication about benefits, harms, and evidence uncertainties of new medicines, specifically new cancer medicines.   

For more than 2 decades, Dr. Wagner has led training programs in pharmaceutical policy in the U.S., Europe, Africa, and Asia.  She has mentored more than 40 pre- and post-doctoral research fellows and colleagues from more than 20 countries. 

Dr. Wagner holds a German master-equivalent degree in pharmacy, a doctorate in clinical pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences, a Master of Public Health degree in international health and a Doctor of Public Health degree in epidemiology from the Harvard School of Public Health. She completed training programs in bioethics including the Harvard Medical School Fellowship in Bioethics.  She has received prestigious mentorship excellence awards and served as a coach for the ncfdd Faculty Success Program.

Focus Areas:

Health Policy

Organizational Ethics

Cancer Therapeutics